Original Article: Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer (phase 3 VOLGA trial) nej.md/4z7dQFm
#ESMO26 | @myESMO
Matsu retweeted
🎉#JSUO2026 プログラムのご案内🎉
JSUO-JSUP Joint Session
「泌尿器腫瘍診断のポイントとビットフォール~病理医・放射線科医とのコラボレーション~」
🗓️ 10月25日(日)16:20~17:20
📍 第1会場(KIITOホールA)
泌尿器腫瘍診断の要点を、病理医・放射線科医と連携して考えるセッションです✨
Matsu retweeted
VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy alone (0.51 and 0.58 respectively). pCR 40-45% with ctDNA clearance rates of 60%. High rates of adjuvant IO therapy uptake and low rates of neuropathy suggest potential advantages of this approach which focuses the ADC in the neoadjuvant phase. It’s likely to be attractive for patients.
Matsu retweeted
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.
⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy.
🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.
#BladderCancer #GUOnc @OncoAlert @BladderCancerUS
Matsu retweeted
ChatGPT・Claude・Gemini
全部で使える"神プロンプト15選"
まとめました。
コピペでそのまま使えるので
ブクマしておくと
明日からの作業マジで変わります。
Matsu retweeted
🎆London calling : 13 abstracts from the Team Jikei Urology have been accepted by the EAU 🇬🇧🇬🇧🇬🇧
See you in London!
@gehi87
@F_Urabe
@Macchan1055
@ene1the1r0nk1d
Matsu retweeted
Cannabis use and risk of testicular germ cell tumour: a systematic review and meta-analysis - Our findings highlight cannabis use as a significant modifiable risk factor for the development of TGCT, particularly NSGCT. pubmed.ncbi.nlm.nih.gov/4118…
Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Can... sciencedirect.com/science/ar…
71
Matsu retweeted
JSESイラコン 17
📌下大静脈腫瘍塞栓を伴う右腎癌のロボット手術
📝下大静脈の遠位はステープリングし離断、肝臓を脱転し下大静脈は頭側でクランプ、さらにプリングル法で肝血流を制御し下大静脈を切開、腫瘍を直接確認して下大静脈ごと切除。この一連の手技を1枚のイラストで表現。
🖊Dr.Cazz
#JSESイラストコンテスト #JSES_illustration_contest
Matsu retweeted
What is the role of #PSA response in androgen receptor pathway inhibitors (#ARPI)?
eu-focus.europeanurology.com…
@DrShariat @amerseburger @Albert0Briganti @dr_rajwa @Silke_Gillessen
Matsu retweeted
We are happy to share our recent publication,
"Effects of the NAC and Adjuvant Chemotherapy on the Prognosis of MIBC Treated With Radical Cystectomy".
Our findings showed that 3 or more NAC cycles plus AC may have limited effects on OS in MIBC patients who received RC.
Matsu retweeted
続き
②NACの使用率における日本の常識は56.1%(日本の泌尿器科医は優秀!)、術後補助化学療法は26.9%
③NAC2コースも3コースも効果が変わらなかった
④NAC後の術後補助化学療法は上乗せ効果が弱い可能性(今は術後補助免疫療法が標準です)
onlinelibrary.wiley.com/doi/…… pic.x.com/gMz9hXwCu3
Matsu retweeted
Very happy to share our recent meta-analysis on perirectal spacers in patients treated with radiotherapy for prostate cancer! termedia.pl/Perirectal-space…
@rstando @GiulioFrancoli1 @CZamboglou @agata_suleja @fazekasMD @Macchan1055 @mleapman @dr_rajwa @stephane_supiot @DrShariat
Matsu retweeted
Impact of opium on bladder cancer incidence: A systematic review and m... sciencedirect.com/science/ar…
I'm happy to announce that I've been accepted into the YAU Prostate Cancer Working Group! 🤩 Excited to collaborate with YAU members on future research. 🔬🚀 @GMarra_MD @dr_rajwa
Matsu retweeted
🌟📢 @ASCO #GU25 | Abstract #17
🔬 LuPSMA + Enzalutamide improves OS & QoL in poor-risk mCRPC (ENZA-p trial).🌟
@drlouiseemmett @MartinStockler
📊 Key Findings (N=162, median FU: 34 months)
✅ OS: 34 vs. 26 months (HR 0.55, P=0.005)
✅ Improved deterioration-free survival at 12 months:
OHQL: 40% vs. 13% (P<0.001)
Physical function: 38% vs. 17% (P<0.001)
✅ Lower pain & fatigue scores until progression
📌 Clinical Impact:
🔹 LuPSMA + Enza enhances survival & QoL in poor-risk mCRPC.
🔹 Better symptom control with manageable toxicity.
👥 @APCCC_Lugano @OncoAlert @UroToday @GUOnc @PCFnews #ProstateCancer #mCRPC #GUcancer
Matsu retweeted
🌟📢 @ASCO #GU25 |
Abstract #658
🔬 Adjuvant nivolumab (NIVO) improves DFS & OS in muscle-invasive bladder cancer (MIBC) in CheckMate 274.
@MattGalsky
📊 Key Findings (N=560, FU: 36.1 months)
✅ DFS (NIVO vs. PBO)
All MIBC: 25.6 vs. 8.5 months (HR 0.63)
With prior NAC: 19.6 vs. 8.3 months (HR 0.58)
Without prior NAC: 25.9 vs. 13.7 months (HR 0.69)
✅ OS (NIVO vs. PBO)
All MIBC: NR vs. 39.9 months (HR 0.70)
PD-L1 ≥ 1%: NR vs. 37.6 months (HR 0.48)
With prior NAC: 55.2 vs. 40.2 months (HR 0.74)
📌 Clinical Impact:
🔹 Adjuvant NIVO remains the standard of care in high-risk MIUC & MIBC.
🔹 Potential curative option post-surgery.
👥 @ASCO @OncoAlert @UroToday @gu_onc @apolo_andrea @GUOncologyNow @MattMilowsky @ScotNiglio @XinanSheng @HouedeNadine @ERPlimackMD #BladderCancer #GUcancer #CheckpointInhibitors
How To Write a Response to Reviewers - ScienceDirect sciencedirect.com/science/ar…
53


































